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Human immunode�ciency virus type 1 (HIV-1) transmitted drug resistance (TDR) is an important public health issue. In Brazil,
low to intermediate resistance levels have been described. We assessed 225 HIV-1 infected, antiretroviral naïve individuals, from
HIV Reference Centers at two major metropolitan areas of Sao Paulo (Sao Paulo and Campinas), the state that concentrates most
of the Brazilian Aids cases. TDR was analyzed by Stanford Calibrated Population Resistance criteria (CPR), and mutations were
observedin17individuals(7.6%,95%CI:4.5%–11.9%).Seventy-sixpercentofgenomes(13/17)withTDRcarriedanonnucleoside
reverse transcriptase inhibitor (NNRTI) resistance mutation, mostly K103N/S (9/13, 69%), potentially compromising the
preferential�rst-linetherapysuggestedbytheBrazilianHIVTreatmentGuidelinethatrecommendsefavirenz-basedcombinations.
Moreover, 6/17 (35%) had multiple mutations associated with resistance to one or more classes. HIV-1 B was the prevalent subtype
(80%); other subtypes include HIV-1 F and C, mosaics BC, BF, and single cases of subtype A1 and CRF02_AG. e HIV Reference
Center of Campinas presented more cases with TDR, with a signi�cant association of TDR with clade B infection (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃).
1. Introduction
Access to free antiretroviral therapy (ART) is part of the
Brazilian response to the Aids epidemic and transmitted
drug resistance (TDR); it has been a concern since the
introductionofhighlyactiveantiretroviraltherapy(HAART)
in the late 1990s [1]. TDR surveillance is an important
strategy to monitor the emergence of genetic resistance as
it may impact ART eﬃcacy [2]. is issue was especially
sensible in Brazil that deployed a free ARV program in
the late 90s amidst a suboptimal health care system. is
initiative could boost the emergence of transmitted drug
resistancevariantsandjeopardizeHumanimmunode�ciency
virus (HIV-1) treatment [3]. However, most studies in Brazil
have shown TDR prevalence similar to that observed among
developed countries. Two recent Brazilian national surveys
had accessed this issue [4, 5] but included a small represen-
tation of São Paulo metropolitan areas. We and others have
analyzed mutations in treatment-naive individuals [6–12];
buttotracetrendsforTDRprevalence,continualmonitoring
is necessary.
We analyzed ARV naïve individuals living with HIV/
Aids,recruitedatHIVReferenceCentersfromthetwomajor
metropolitan areas of Sao Paulo state to investigate the TDR
prevalence. ese metropolitan areas concentrate 44% of
noti�ed Aids cases of Sao Paulo state and about one third of
the Brazilians living with HIV/Aids.
2. Materials and Methods
People living with HIV, asymptomatic and naïve to ART
were recruited at outpatient Clinic or Voluntary Counseling2 Advances in Virology
and Testing (VCT) at two metropolitan areas, the HIV State
Reference Center at the city of Sao Paulo and the Municipal
HIV Reference Center at the city of Campinas. Volunteers’
selection was conducted by their primary physicians’ or
by VCT counseling personnel, with additional revision to
con�rm ARV exposure history. Individuals that agreed to
participate were interviewed by clinical staﬀ to access risk,
review of potential previous exposures to ART (e.g., MTCT
or postexposure prophylaxis), and document the knowledge
of a partnership (sexual or sharing of drug paraphernalia)
with individuals using ARV. Blood samples were collected
from May 2008 to November 2009. Brie�y, HIV-1 RNA
was extracted with QIAamp viral RNA mini kit (Qiagen,
Germany) and reverse transcribed with random primers and
Superscript III enzyme (Invitrogen, USA). In samples of
low HIV-1 RNA viral load or negative plasma detection,
DNAfromperipheralbloodmononuclearcells(PBMCs)was
extracted (Qiagen, Germany). Nested PCR products were
sequencedusingBigDyeterminatorsatanABI3100Genetic
Analyzer (ABI, USA) to evaluate protease (PR, codons 1 to
99) and partial reverse transcriptase (RT, codons 1 to 235)
genes as previously described [6]. Sequences were manually
edited using Sequencher 4.7 soware (Gene Codes, USA).
Ambiguous DNA bases (mixtures) at resistance associated
codonswereconsideredatsequenceedition.HIVgenotyping
resistance test results were reported to the HIV Reference
Centers. TDR was de�ned according to the Calibrated
Population Resistance Version 6.0 (CPR, Stanford Database,
SDRM 2009), an algorithm speci�cally designed for the epi-
demiologicsurveillanceofHIV-1transmitteddrugresistance
mutations(DRMs)[13].InternationalAntiviralSociety(IAS)
2011resistancelist[14]wasadditionallyconsideredtoevalu-
atetheimpactofresistanceinARTresponse,whichconsiders
allmutationsthatimpactARVsusceptibility.Tocontributeto
HIV molecular epidemiology surveillance, HIV-1 subtyping
was performed at NCBI genotyping and REGA HIV subtyp-
ing tools and con�rmed by phylogenetic methods (PAUP
∗
4.10b), using evolution model selected by ModelTest3.7.
Sequences are available at GenBank with accession numbers:
HM533970 to HM534205; HQ015155 to HQ015157.
e Institutional Review Boards of the participating HIV
Reference Centers and Adolfo Lutz Institute approved this
study.
3. Results
Of the 243 HIV-1 infected individuals enrolled in the study,
partial HIV-1 pol sequences from 230 (95%) individuals
were successfully sequenced (96% from plasma and 4% from
PBMC). e inclusion criterion of no previous exposure to
ARTwasmetby225individualsandincludedintheanalysis.
Among the study individuals, six females had previous expo-
sure to MTCT prophylaxis, documented at the interview.
Most of the sequences analyzed from these women (3/4)
exhibited one or more DRM but were not included in TDR
prevalence estimate that was generated from the 225 ART
naive individuals. Also, one case with unknown information
of exposure to ART, but with history of undetectable viremia
in previous years, had several resistance mutations and was
excluded from analysis. Unprotected exposure among men
who have sex with men (MSM) was the most frequent trans-
mission route. Table 1 depicts demographic and laboratorial
data from study volunteers at Campinas and São Paulo sites.
According to Stanford CPR, TDR mutations were
detected in 17 sequences (7.6%, 95% CI: 4.5%–11.9%). e
prevalence of TDR at Campinas was 9.6% (15/156) and at
Sao Paulo 2.9% was (2/69) (𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃). e two individuals
from Sao Paulo site had more extensive TDR patterns, both
withmutationstoproteaseinhibitor(PI)andNNRTIandone
with additional resistance mutations to nucleoside reverse
transcriptase inhibitor (NRTI) (Table 2). At Campinas site,
most TDR were NNRTI-resistance mutations (73%, 11/15),
followed by PI and NRTI (20%, 3/15 each), and 2 sequences
were resistant to two ARV classes. Overall, 76% (13/17)
of sequences bearing at least one TDR had an NNRTI
resistance, 71% (12/17) impairing susceptibility to efavirenz
(EFV).K103N/S(53%,9/17)wasthemostfrequentmutation
observed. No association of TDR to transmission risk group
or gender was observed. Also, individuals referring sexual
partner on ART have a similar number of TDR (𝑃𝑃 𝑃 𝑃𝑃𝑃).
C a m p i n a st e n d e dt oh a v em o r ec a s e sw i t hT D R ,w i t ha
signi�cant association of TDR to HIV-1 B infection using
e i t h e rC P Ro rI A Sl i s t( 𝑃𝑃 𝑃 𝑃𝑃𝑃𝑃 ).
To evaluate the impact of mutations or polymorphisms
associated to resistance, we additionally used the 2011 IAS
updated mutation list, and 32 sequences (14.2%) had at least
one IAS major mutation (Table 2).BothIASandCPRcriteria
were used to assess the relevance of mutations on successful
therapy in patients where, according the Brazilian treatment
guidelines, ART was recommended. e genotyping test
reports were available to the HIV Reference Centers, and
the ART was selected taking into account the test report.
Virological responses of patients with TDR were assessed
until 2012 (Table 2). Out of the 33 individuals with drug
resistance mutation, 18 initiated ART, and 16 had clinical
and laboratory information, some cases with followup of 37
months. is followup showed that all but one individual
(BR09CA175), who had documented adherence issues, were
virally suppressed at last observation (Table 2).
4. Discussion
Among this population of antiretroviral naïve HIV-1-
infected individuals attending the Campinas and São Paulo
Reference Centers, transmitted drug resistance was detected
overall in 7.6% of individuals. is TDR prevalence was
similar to that reported in other regions of Brazil that
used Stanford CPR criteria for these estimates, [4–12, 15].
e reasons for this stabilization, or even decrease of TDR
prevalence in most surveys are unclear, but there may well
be a plateau where the circulation of mutated isolates may
come to some equilibrium, depending on multiple factors
as the ARV therapy usage, therapy combinations, adherence,
and social networking, among others. e followup of the
small but consistent increase in TDR in Africa aer the
introduction of treatment programs [2] will allow verifying
this hypothesis.Advances in Virology 3
T 1: Demographic and laboratorial characteristics of the study individuals according to transmitted drug resistance (TDR).
TDR (𝑛𝑛 𝑛 𝑛𝑛) Without TDR (𝑛𝑛 𝑛 𝑛𝑛𝑛) Total (𝑛𝑛 𝑛 𝑛𝑛𝑛)
Age (year old) 32 (29–40) 34 (29–40) 34 (29–40)
Gender (male) 23 (69.7%) 138 (71.9%) 161 (71.6%)
CD4+ T cells (cells/mm
3) 461 (322–631) 475 (353–623) 463 (344–626)
Viral load (Log10) 4.1 (3.6–4.8) 4.3 (3.6–4.7) 4.3 (3.6–4.7)
HIV exposure
MSM 20 (61%) 100 (51%) 120 (52%)
Heterosexual 11 (33%) 76 (41%) 87 (40%)
IDU 1 (33%) 1 (0.5%) 2 (0.4%)
HIV-1 subtype (partial pol)
A1 0 1 (0.5%) 1 (0.4%)
B 31 (94%) 149 (78%) 180 (76%)
F 0 14 (7%) 14 (6%)
C 1 (33%) 15 (8%) 16 (7%)
CRF02_AG 0 1 (0.5%) 1 (0.4%)
Recombinant mosaic 1 (33%) 12 (6%) 13 (6%)
Surveillance site
Campinas 26 (79%) 130 (68%) 156 (69%)
São Paulo 7 (21%) 62 (32%) 69 (31%)
In this study, most individuals had high CD4+ T cell
counts at collection, with a median of 463cells/mm
𝑛. How-
ever,25%hadCD4+Tcellcountsbelow350cells/mm
𝑛,CD4
counts that were indicative of ARV treatment by Brazilian
Guidelines at the time. Currently, the recommendation is
starting therapy when CD4+ T cells counts drops below
500cells/mm
𝑛. Although not the focus of this study, a
small number of women exposed to MTCT prevention were
recruited but excluded in TDR estimates. ese women
had signi�cant resistance pro�le and constitute a population
segment that should have access to pretreatment genotype
test.
In Brazil, over 200,000 patients are currently using ART,
with 80,000 in São Paulo state. However, some of these
patients are not virally suppressed, representing a potential
source of transmitted drug resistance. On the other hand,
a large number of untreated individuals harbor wild-type
variants (estimated to be at least twice the number of treated
individuals), another source of HIV transmission that may
play an important role in the low prevalence of documented
transmitted resistance, consistent across most studies. Addi-
tionally, low �tness or other biological limitations in the
transmissibility potential of these variants might also have
a role in the observed prevalence of resistant strains. More
important than point estimates of transmitted resistance
would be to trace its tendency in time. Trends in TDR based
on sequential assess of sentinel sites are probably one of the
best ways to monitor TDR. e Brazilian AIDS Program
have conducted a large TDR survey [4], but diﬀerences in
methodology, design, and participating sites at a previous
study [8] limit the comparability of these evaluations. Other
recent national study [5], conducted almost at the same time,
indicate similar numbers, with estimates at 5–15%, applying
the HIV reshold Survey methodology from WHO. For
sites in the Sao Paulo state, the estimates generated at these
studies ranged from 0 to 15% [4, 5]. However, these studies
had small samples size at sites in the state, ranging from
7 to 34 individuals, which decreased the strength of these
to estimates. ese diﬀerences probably also re�ect issues
as sampling eﬀects, study design, stringency in the con�r-
mation of ART na�ve status, and criteria for de�ning TDR.
Additionally, one of these studies [4] found an association
of partnership of individuals using ART with the presence of
TDR. is issue was also evaluated here, and the number of
TDRwassimilaramongcasesreportingapartnerusingART.
As expected for the subtype prevalence at this region
of Brazil, HIV-1 subtype B was the most common in both
sites. However, the proportions of HIV-1 C and BC mosaics
were higher than previously reported in the area. is is
further detailed elsewhere [16]. Also, a single CRF02_AG
was identi�ed, and although it is the most disseminated
HIV recombinant form worldwide, it is rather uncommon
at South America, with a report of its presence in Brazil
[17]. In this study, we found an association within Campinas
sequences of transmitted resistance to subtype B (𝑃𝑃 𝑛 𝑃𝑃𝑃𝑛)
using either CPR or IAS criteria, in agreement with Sprinz et
al. [4], where TDR was predominantly found among subtype
B infected individuals.
e impact on treatment eﬃcacy is the central problem
of TDR. e high prevalence of NNRTIs resistance among
cases with TDR is a potential problem as the Brazilian
HIV Treatment Guideline recommends NNRTI, especially
efavirenz-based HAART, as a preferential �rst-line therapy.
Considering the low genetic barrier of NNRTI, which a
single DRM may confer high level of resistance to the
entire class, these patients may actually be initiating ARV
with a functional dual therapy, leading to a partial viral
suppression, a favoring environment for the emergence of4 Advances in Virology
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further resistance mutations. Moreover, no decrease in viral
�tnessisexpectedform uta tionstothisclass,andtheytendto
persistlongerandbemorereadilydetectablethanothersthat
interfere with viral �tness, such as M184V. Persistence as a
detectablemutationinpopulationsequencingdoesnotmean
the same as persistence throughout the viral quasispecies,
and it is conceivable that mutations detected in population
sequencing may be considered “sentinel mutations.” ese
could indicate the presence of additional resistance muta-
tions, below detection limits of this sequencing approach,
which could interfere with treatment success [18]. If those
detectable mutations signs that other occult mutations exist,
one would expect treatment compromise even if physicians
have access to pretreatment genotype. Although the number
of cases is small, our study documented relatively long-term
treatment outcome. As the physicians received the genotype
test results, cases initiating HAART aer the test result had
a therapy in�uenced by the genotyping test. In most cases a
combination therapy was chosen to include drugs not pre-
dicted to be aﬀected by the observed DRM. is would have
circumvented the direct eﬀect of the detected mutation but
not of the occult, additional resistances supposedly present
in minority variants. However, the presence of TDR in these
individuals did not have an impact in viremia control, and
the only treated case without suppression had documented
adherence issues.
5. Conclusion
We observed low to intermediate levels of transmitted drug
resistance mutations (7.6%), with most of them impairing
susceptibility to efavirenz, a preferential ARV in �rst-line
therapy at Brazil, con�rming previous �ndings in the coun-
try. It is important both to monitor transmitted resistance
trends and to de�ne algorithms that might subsidize treat-
ment alternatives where access to genotype test prior to
therapyinitiationtoallindividualsmaybeunrealistic.Onthe
other hand, targeting genotypic test to population segments
most susceptible to TDR may be cost eﬀective. is would
have both the potential bene�t in HIV treatment response
and an impact in reducing the drug resistance transmission
of to the overall population.
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